Register to receive a free U.S. Patient Monitoring Device and Equipment Market report synopsis and brochure
Philips N.V. (NYSE: PHG) announced today that it received FDA 510(k) clearance for it’s Avalon CL Fetal Monitoring solution (Avalon CL). This solution aims to provide consistent monitoring of the mother and child while reducing the amount of cables. Cableless transducers transmit fetal and maternal vital signs information to a fetal monitor via the base station.
By eliminating the discomfort of managing cables, Avalon CL allows women to move around and find the most comfortable position during labor, offering them more flexible birthing options, including showers and tubs. The solution continuously measures and transmits fetal heart rate and maternal pulse, uterine activity, and fetal or maternal ECG, allowing consistent monitoring while the mother is on the move.
“Conventional fetal monitoring solutions present limitations for physicians and patients alike,” said Mike Mancuso, CEO of Philips Healthcare’s patient care and monitoring solutions unit, in the release. “This latest cableless technology enhances clinician confidence and allows women more flexibility and freedom of movement during labor, which can be very beneficial to the woman and child.”
Avalon CL includes patented Smart Pulse technology designed to automatically detect heart rate coincidence between the maternal pulse and the fetal heart rates, even for twins and triplets. It also performs electrocardiograms on the mother and child.